Primary Sjögren’s syndrome: Pathophysiological, clinical and therapeutic advances - 09/12/09
pages | 4 |
Iconographies | 1 |
Vidéos | 0 |
Autres | 0 |
Abstract |
Primary Sjögren’s syndrome was long a vexing dilemma, as the underlying pathophysiological mechanisms remained obscure, disease activity was challenging to evaluate, and no specific treatments were known to be effective. However, recent years have witnessed major advances in these three areas. Convincing evidence has been obtained that innate immunity, most notably mediated by the interferons, plays a role in the initial B-cell activation. A disease activity score was developed during a consensus conference sponsored by the EULAR. Even more importantly, B-cell depletion constitutes a highly promising therapeutic approach. Thus, rituximab was effective in two controlled clinical trials.
Le texte complet de cet article est disponible en PDF.Keywords : Sjögren’s syndrome, Primary, Disease activity score, B-lymphocytes, Interferons, Rituximab
Plan
Vol 76 - N° 6
P. 591-594 - décembre 2009 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?